The US Food and Drug Administration on Wednesday approved the second GLP-1 pill for weight loss, adding another option to a ...

The U.S. Food and Drug Administration has approved Eli Lilly’s new weight-loss GLP-1 pill, orforglipron, which will be sold ...

The pill will be branded as Foundayo and shipping will begin on Monday and be available at pharmacies and on telehealth ...

Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity ...

A new daily pill, called Foundayo, is the second oral GLP-1 to reach the market in recent months, following the FDA approval ...

The daily pill called Foundayo got a fast track through the Food and Drug Administration. It will compete with the pill form ...

The Federal Drug Administration (FDA) has approved a new once-daily weight-loss pill from Eli Lilly, adding to the bevy of ...

Orforglipron is the second daily weight-loss pill to hit the market. The first was the Wegovy pill, from Novo Nordisk, which ...

The drugmaker’s pill will take on a rival from Novo Nordisk in the booming multibillion-dollar obesity drug market.

FDA approves Eli Lilly’s daily weight‑loss pill Foundayo, a fast‑tracked GLP‑1 drug offering a new oral option for obesity ...

Small-molecule medicine will compete with Novo Nordisk’s peptide pill, which has been on the market since January ...

This innovative oral GLP-1 is a ‘small molecule’ medication that, unlike the Wegovy pill, doesn’t require that you take it on ...